Biotricity

Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It is also involved in delivering remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm’s FDA-approved Bioflux MCT technology is comprised of monitoring device and software components, which are made available to the market to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Biotricity achieves positive EBITDA in Q2 2025, poised for growth

Biotricity's Q2 2025 performance showcased positive EBITDA, revenue growth, and operational improvements.
The company's strategic strengths lie in expanding capabilities, forming partnerships, and meeting market demand.
Challenges include sustaining profitability, reducing expenses, and navigating competitive pressures.
Opportunities for Biotricity include growth through partnerships, revenue model optimization, and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biotricity, Inc. is a medical technology company, which engages in biometric data monitoring solutions. It operates through the following segments: Resting (Non-stress) ECG Systems, Stress ECG Systems, and Holter Monitoring Systems. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

First Time in the Company's History REDWOOD CITY, Calif. , Dec. 3, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB: BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced achieving positive free cash flow, a measure of financial health and another major milestone towards profitability.

Biotricity Achieves Positive Free Cash Flow Milestone

Biotricity, Inc. (OTC:BTCY) Q2 2025 Earnings Conference Call November 15, 2024 4:30 PM ET Company Participants Dr. Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - Chief Financial Officer Conference Call Participants Kevin Dede - H.C. Wainwright Operator Greetings.

Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript

REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc.  (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the second quarter of fiscal 2025 year and (unaudited) ended September 30, 2024.

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025

Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc.  (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 15, 2024.

Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th

The company has achieved EBIDTA positive on a go-forward cash basis REDWOOD CITY, CA / ACCESSWIRE / October 3, 2024 / Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company that is reshaping the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today reports compelling financial and strategic advancements that will propel the company towards profitability by the end of Fiscal Q4. Biotricity is now on an accelerated trajectory to profitability due to growing revenues from sales and strategic partnerships, improving margins, and an earlier than expected milestone of achieving EBITDA positive on a go-forward cash basis.

Biotricity Provides Updated Guidance for Earlier than Expected Path to Profitability due to Growing Revenues and Improving Margins

REDWOOD CITY, CA / ACCESSWIRE / September 26, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting-edge remote monitoring and diagnostic solutions, announces its inclusion as a supplier to another major medical system that encompasses 60,000 care providers over 400 hospitals and 400 care centers. In the U.S. today, 121.5 million adults have some form of cardiovascular disease.

Biotricity Announces Inclusion as a Supplier to A Prominent Medical System That Services 21 States

REDWOOD CITY, CA / ACCESSWIRE / September 19, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting edge remote monitoring and diagnostic solutions, announces the launch of a new cardiac monitoring pilot program with a top hospital system. With 90% of U.S. adults at risk of developing cardiovascular disease and a projected shortage of up to 124K physicians in the next 12 years, the demand for Biotricity's innovative cardiac monitoring solutions has never been more urgent.

Biotricity Kicks off Another Pilot Program with a Major Hospital System that Services over 800K Individuals

The Company shows continued progress towards cash-flow break even and profitability Recurring Technology Fee (SaaS) revenue - over 94% of total revenue with a 76% gross margin, which rose over 400 basis points and is expected to continue to trend higher Gross margins improved significantly to 73.8 from 63.5% in the same period last year, and 59.6% 2 years earlier Reduced SG&A to $3 million, down 16% compared to same period last year Operating loss of $1.1 million, indicated efficiency gains of $1.2 million from the preceding year quarter - a 51.8% improvement Growth in revenue of 6% YOY to $3.2 million EBITDA and Adjusted EBITDA improved by 18.9% and 49.8%, respectively, from the corresponding period in the prior year; Quarter over preceding Quarter, EBITDA improved by $1M, or 36%, whereas Adjusted EBITDA improved by $1.5M or 59%. Comprehensive loss was reported at $6.9 million, due to one-time non-cash items of $3.2 million; removing these would have resulted in a net loss of $3.7 million, consistent with prior year levels of $3.8 million due to interest rate increases that countered the impact of efficiency gains REDWOOD CITY, CA / ACCESSWIRE / August 21, 2024 / Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the first quarter of fiscal 2025 year ended June 30, 2024.

Biotricity Reports Continued Margin Improvement and Reduced Losses in its First Quarter Fiscal Year 2025

Lobo EV Technologies Ltd

ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (Nasdaq:LOBO) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m.

LOBO EV and Nexalin Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

REDWOOD CITY, CA / ACCESSWIRE / July 22, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced ongoing improvements in operational efficiency, scalability and margin performance driven by the latest enhancements to the company's proprietary AI Cloud platform. The latest version of Biotricity's AI Cloud has improved the company's tech stack efficiency by 20%, which is expected to result in a topline margin improvement of 200 to 300 basis points (2 to 3%) in the coming quarters.

Biotricity Announces Continued Margin Improvement Driven by its Proprietary AI Cloud

Enlivex Therapeutics Ltd

ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m.

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

bioAffinity Technologies Inc

ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET).

Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

REDWOOD CITY, CA / ACCESSWIRE / July 11, 2024 / Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its accelerated timeline to achieving EBITDA positive. The company now expects to reach this significant milestone before the end of calendar 2024, earlier than previously anticipated.

Biotricity Announces Accelerated Path to EBITDA Positive

REDWOOD CITY, CA / ACCESSWIRE / July 10, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the launch of a new cardiac monitoring pilot program with a prominent hospital group encompassing 60 sites spread across multiple states. Biotricity's cardiac monitoring solution is the only three-channel connected solution in the world.

Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program

Democratizing cardiac health with convenient, rapid, and reliable results REDWOOD CITY, CA / ACCESSWIRE / June 28, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announced its groundbreaking direct-to-consumer heart health screening service, HeartSecure, is now available for purchase online at HeartSecure. Heart disease remains the leading cause of death worldwide, with someone succumbing to cardiovascular disease (CVD) every 1.5 seconds.

Biotricity Launches HeartSecure: Immediate, At-Home Cardiac Screening Now Available

Biotricity, Inc. (NASDAQ:BTCY ) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Michael Donovan - H.C. Wainwright Operator Greetings, and welcome to the Biotricity Fiscal Year 2024 Financial Results and Business Update Call.

Biotricity, Inc. (BTCY) Q4 2024 Earnings Call Transcript

FY24 revenue up 25.2% YOY FY24 margins improved 1280 basis points to 69.3%, from 56.5% in the prior year; Q4-FY24 margins improved to 71.5%; margin expansion forecasted to continue FY24 operating expenses lower by 17.6% YOY Negative EBITDA reduced by $7.2 million - an improvement of 44.6% -- accelerating the Company's path to breakeven and EBITDA positive REDWOOD CITY, CA / ACCESSWIRE / June 27, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2024. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "Fiscal 2024 has been a year of massive transformation for Biotricity.

Biotricity Reports Strong Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses for Fiscal Year 2024, Accelerating the Company's Path to Profitability

REDWOOD CITY, CA / ACCESSWIRE / June 26, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its fourth quarter and fiscal year 2024 financial results and business update call on Thursday, June 27, 2024. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.

Biotricity to Host Fourth Quarter and Fiscal Year 2024 Financial Results and Business Update Call on June 27

REDWOOD CITY, CA / ACCESSWIRE / June 12, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announces the highly anticipated launch of its direct-to-consumer heart health screening program, HeartSecure. Someone in the world dies of cardiovascular disease (CVD) every 1.5 seconds.

Biotricity Launches Direct-to-Consumer Heart Health Screening Service, HeartSecure, Making Heart Health Services Accessible in Response to the #1 Global Killer, Poising Company to Access the Growing Home Diagnostics Market

Company expects Loss from Operations to decrease by over 40% YoY and Margin Improvement by over 10% YoY REDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is excited to provide guidance for its upcoming Year-End Results. Biotricity announces expectations to meet analyst revenue target, while beating margin and loss targets.

Biotricity Provides Year-End Guidance with Expectations to Meet Analyst Revenue Target and Beating Loss and Margin Targets

REDWOOD CITY, CA / ACCESSWIRE / June 4, 2024 / Biotricity Inc.] (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is thrilled to announce that the majority of its existing Preferred A shareholders have converted 97% of all the preferred A shares into Restricted Common Stock, increasing their support and commitment to the Company. "This recent conversion shows the growing enthusiasm our long-term shareholders have for the Company and their confidence in the execution and upcoming milestones of the company," remarked Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity.

Biotricity Preferred Shareholders Show Increased Commitment and Support of the Company by Converting Almost All Preferred A Shares into Restricted Common Stock

REDWOOD CITY, CA / ACCESSWIRE / May 30, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is thrilled to announce plans for a revolutionary direct-to-consumer program, HeartSecure, to support the 127M Americans at risk for heart disease. HeartSecure offers the first-of-its-kind, home-based cardiac screening service, empowering individuals to proactively check their heart health from the comfort of their homes.

Biotricity Announces the Upcoming Launch of the First-Ever Direct-to-Patient Cardiac Screening Service, Targeting the $1.05B Home Heart Health Market

REDWOOD CITY, CA / ACCESSWIRE / April 30, 2024 / Biotricity Inc. (NASDAQ:BTCY), a groundbreaking Technology-as-a-Service (TaaS) company committed to delivering cutting-edge medical and consumer diagnostic healthcare solutions, announces the expansion of its cardiac diagnostics portfolio through strategic partnerships with a leading home-based neurology company and a leading home-based sleep apnea diagnostic company. Individuals suffering from sleep or neurological disorders have elevated risks for cardiac issues.

Biotricity Expands Market Reach to Pulmonary and Neurology Fields Through Latest Partnerships with Two Leading Home-Based Diagnostic Companies

REDWOOD CITY, CA / ACCESSWIRE / April 26, 2024 / Biotricity Inc. (NASDAQ:BTCY), a pioneering Technology-as-a-Service (TaaS) company dedicated to delivering top-of-the-line medical diagnostic and consumer healthcare solutions, announces high demand for its latest breakthrough device, Biotres Pro. This device is easy to wear, resulting in excellent patient compliance and a higher selling price.

Biotricity's Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest from Existing and New Customers

REDWOOD CITY, CA / ACCESSWIRE / April 18, 2024 / Biotricity Inc. (NASDAQ:BTCY) a leading Technology-as-a-Service (TaaS) company at the forefront of medical diagnostics and consumer healthcare, announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline data collection processes.

News for Biotricity Stock (BTCY)